These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 28536100)

  • 1. Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy.
    Dammeijer F; Lievense LA; Kaijen-Lambers ME; van Nimwegen M; Bezemer K; Hegmans JP; van Hall T; Hendriks RW; Aerts JG
    Cancer Immunol Res; 2017 Jul; 5(7):535-546. PubMed ID: 28536100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS.
    de Goeje PL; Klaver Y; Kaijen-Lambers MEH; Langerak AW; Vroman H; Kunert A; Lamers CHJ; Aerts JGJV; Debets R; Hendriks RW
    Front Immunol; 2018; 9():2034. PubMed ID: 30245692
    [No Abstract]   [Full Text] [Related]  

  • 3. Antigen spreading-induced CD8+T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells.
    Yu Z; Tan Z; Lee BK; Tang J; Wu X; Cheung KW; Lo NT; Man K; Liu L; Chen Z
    Oncotarget; 2015 Oct; 6(32):32426-38. PubMed ID: 26431275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
    Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
    Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma.
    Yuan J; Kashiwagi S; Reeves P; Nezivar J; Yang Y; Arrifin NH; Nguyen M; Jean-Mary G; Tong X; Uppal P; Korochkina S; Forbes B; Chen T; Righi E; Bronson R; Chen H; Orsulic S; Brauns T; Leblanc P; Scholler N; Dranoff G; Gelfand J; Poznansky MC
    J Hematol Oncol; 2014 Feb; 7():15. PubMed ID: 24565018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment.
    Peranzoni E; Lemoine J; Vimeux L; Feuillet V; Barrin S; Kantari-Mimoun C; Bercovici N; Guérin M; Biton J; Ouakrim H; Régnier F; Lupo A; Alifano M; Damotte D; Donnadieu E
    Proc Natl Acad Sci U S A; 2018 Apr; 115(17):E4041-E4050. PubMed ID: 29632196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colony-Stimulating Factor 1 Receptor Blockade Inhibits Tumor Growth by Altering the Polarization of Tumor-Associated Macrophages in Hepatocellular Carcinoma.
    Ao JY; Zhu XD; Chai ZT; Cai H; Zhang YY; Zhang KZ; Kong LQ; Zhang N; Ye BG; Ma DN; Sun HC
    Mol Cancer Ther; 2017 Aug; 16(8):1544-1554. PubMed ID: 28572167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.
    Mok S; Tsoi J; Koya RC; Hu-Lieskovan S; West BL; Bollag G; Graeber TG; Ribas A
    BMC Cancer; 2015 May; 15():356. PubMed ID: 25939769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pexidartinib and Immune Checkpoint Inhibitors Combine to Activate Tumor Immunity in a Murine Colorectal Cancer Model by Depleting M2 Macrophages Differentiated by Cancer-Associated Fibroblasts.
    Shimizu D; Yuge R; Kitadai Y; Ariyoshi M; Miyamoto R; Hiyama Y; Takigawa H; Urabe Y; Oka S
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of EZH2 methyltransferase decreases immunoediting of mesothelioma cells by autologous macrophages through a PD-1-dependent mechanism.
    Hamaidia M; Gazon H; Hoyos C; Hoffmann GB; Louis R; Duysinx B; Willems L
    JCI Insight; 2019 Sep; 4(18):. PubMed ID: 31534051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is immunotherapy a viable option in treating mesothelioma?
    Dumoulin DW; Aerts JG; Cornelissen R
    Future Oncol; 2017 Aug; 13(20):1747-1750. PubMed ID: 28774186
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells.
    Hegmans JP; Hemmes A; Aerts JG; Hoogsteden HC; Lambrecht BN
    Am J Respir Crit Care Med; 2005 May; 171(10):1168-77. PubMed ID: 15764728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.
    Schuberth PC; Hagedorn C; Jensen SM; Gulati P; van den Broek M; Mischo A; Soltermann A; Jüngel A; Marroquin Belaunzaran O; Stahel R; Renner C; Petrausch U
    J Transl Med; 2013 Aug; 11():187. PubMed ID: 23937772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy.
    Shi G; Yang Q; Zhang Y; Jiang Q; Lin Y; Yang S; Wang H; Cheng L; Zhang X; Li Y; Wang Q; Liu Y; Wang Q; Zhang H; Su X; Dai L; Liu L; Zhang S; Li J; Li Z; Yang Y; Yu D; Wei Y; Deng H
    Mol Ther; 2019 Jan; 27(1):244-260. PubMed ID: 30527756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity.
    Wiehagen KR; Girgis NM; Yamada DH; Smith AA; Chan SR; Grewal IS; Quigley M; Verona RI
    Cancer Immunol Res; 2017 Dec; 5(12):1109-1121. PubMed ID: 29097420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human.
    Aerts JGJV; de Goeje PL; Cornelissen R; Kaijen-Lambers MEH; Bezemer K; van der Leest CH; Mahaweni NM; Kunert A; Eskens FALM; Waasdorp C; Braakman E; van der Holt B; Vulto AG; Hendriks RW; Hegmans JPJJ; Hoogsteden HC
    Clin Cancer Res; 2018 Feb; 24(4):766-776. PubMed ID: 29233904
    [No Abstract]   [Full Text] [Related]  

  • 17. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with anti-programmed cell death 1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation.
    Tada A; Minami T; Kitai H; Higashiguchi Y; Tokuda M; Higashiyama T; Negi Y; Horio D; Nakajima Y; Otsuki T; Mikami K; Takahashi R; Nakamura A; Kitajima K; Ohmuraya M; Kuribayashi K; Kijima T
    Lung Cancer; 2023 Jun; 180():107219. PubMed ID: 37146474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.
    Fujiwara T; Yakoub MA; Chandler A; Christ AB; Yang G; Ouerfelli O; Rajasekhar VK; Yoshida A; Kondo H; Hata T; Tazawa H; Dogan Y; Moore MAS; Fujiwara T; Ozaki T; Purdue E; Healey JH
    Mol Cancer Ther; 2021 Aug; 20(8):1388-1399. PubMed ID: 34088832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.